We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Pacira (PCRX) Down 7.6% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Pacira (PCRX - Free Report) . Shares have lost about 7.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Pacira due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Pacira Q4 Earnings and Revenues Surpass Estimates
Pacira delivered fourth-quarter 2018 earnings of 47 cents per share, surpassing the Zacks Consensus Estimate of 25 cents and also the year-ago bottom line of 38 cents.
Revenues increased 20% year over year to $95.1 million, beating the Zacks Consensus Estimate of $94.4 million as well as the year-earlier number of $79.1 million. Exparel sales came in at $94.4 million for the fourth quarter of 2018, rising 20% year over year. Exparel sales rose 14.8% sequentially.
Quarter in Detail
Pacira’s top line comprises product revenues, other product sales plus royalty revenues. Royalty revenues came in at $0.4 million in the reported quarter, up 77.8% year over year.
Research and development (R&D) expenses (excluding stock-based compensation) surged 47.7% to $13 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) increased 16.2% to $38.7 million in the reported quarter.
2019 Outlook
Pacira raised its guidance for Exparel sales in 2019 and expects the same in the $400-$410 million range. The previous view was in the band of $325-$330 million.
The company’s R&D expenses (excluding stock-based compensation) might be within $60-$70 million while SG&A expenses (excluding stock-based compensation) are anticipated in the $165-$175 million range. Both are increased from the last reported quarter’s projection levels.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates flatlined during the past month. The consensus estimate has shifted 110.71% due to these changes.
VGM Scores
Currently, Pacira has a great Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Pacira has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Pacira (PCRX) Down 7.6% Since Last Earnings Report?
A month has gone by since the last earnings report for Pacira (PCRX - Free Report) . Shares have lost about 7.6% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Pacira due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Pacira Q4 Earnings and Revenues Surpass Estimates
Pacira delivered fourth-quarter 2018 earnings of 47 cents per share, surpassing the Zacks Consensus Estimate of 25 cents and also the year-ago bottom line of 38 cents.
Revenues increased 20% year over year to $95.1 million, beating the Zacks Consensus Estimate of $94.4 million as well as the year-earlier number of $79.1 million. Exparel sales came in at $94.4 million for the fourth quarter of 2018, rising 20% year over year. Exparel sales rose 14.8% sequentially.
Quarter in Detail
Pacira’s top line comprises product revenues, other product sales plus royalty revenues. Royalty revenues came in at $0.4 million in the reported quarter, up 77.8% year over year.
Research and development (R&D) expenses (excluding stock-based compensation) surged 47.7% to $13 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) increased 16.2% to $38.7 million in the reported quarter.
2019 Outlook
Pacira raised its guidance for Exparel sales in 2019 and expects the same in the $400-$410 million range. The previous view was in the band of $325-$330 million.
The company’s R&D expenses (excluding stock-based compensation) might be within $60-$70 million while SG&A expenses (excluding stock-based compensation) are anticipated in the $165-$175 million range. Both are increased from the last reported quarter’s projection levels.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates flatlined during the past month. The consensus estimate has shifted 110.71% due to these changes.
VGM Scores
Currently, Pacira has a great Growth Score of A, a grade with the same score on the momentum front. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Pacira has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.